Recent meta-analyses have shown that the addition of PCSK9 inhibitors or ezetimibe to statin therapy can reduce the incidence of nonfatal MI and stroke in adults with very high or high cardiovascular risk; however, the cardiovascular benefit of this type of therapy has not been demonstrated in individuals with intermediate or low cardiovascular risk [87]. This evidence concerns the gene PCSK9 and stroke disorder.